Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
Company to open new headquarters in 2024
The company sees the business reaching $100mn
The companies will leverage their respective proprietary technology platforms
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
A comprehensive assessment of the organisational systems for governance, management, operations and consistency in delivered results, this certification is an endorsement of the company's export capabilities and manufacturing prowess
Subscribe To Our Newsletter & Stay Updated
